Últimas noticias sobre ProKidney (NASDAQ:PROK) Bolsa

ProKidney

ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's cells isolated from the patient intended for treatment. Its product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.

Wall Street

Equities

News

Eurozone

Commodities

Intraday Update

Markets

Trading Ideas

ABVE

BSLK

MAMK

NDRA

PROK

SKBL

Las bolsas de EE.UU. abrieron mixtas este martes. Te contamos los sectores clave, acciones más destacadas y cómo cierran Europa y Asia.

Wall Street abre en terreno mixto: Dow Jones cae, mientras el Nasdaq avanza

ProKidney Corp. - Class A Ordinary Shares

ProKidney Corp

DRMAW

Trading Halt: Halted at 7:50:00 p.m. ET - Trading Halt: Halt News Pending

DRMA

HCTI

Apollo Asset Management (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APO#NYSE">APO</a>) has outperformed the market over the past 10 years by 10.16% on an annualized basis producing an average annual return of 21.8%. Currently, Apollo Asset Management has a market capitalization of $83.05 billion. 
Buying $1000 In APO: If an investor had bought $1000 of APO stock 10 years ago, it would be worth $7,074.98 today based on a price of $145.32 for APO at the time of writing.
<h3>Apollo Asset Management's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1754004614_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

If You Invested $1000 In This Stock 10 Years Ago, You Would Have This Much Today

Barrington Research analyst Kevin Steinke maintains Quad/Graphics (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QUAD#NYSE">QUAD</a>) with a Outperform and maintains $10 price target.

Price Target

Analyst Ratings

QUAD

Barrington Research Maintains Outperform on Quad/Graphics, Maintains $10 Price Target

Barrington Research analyst Alexander Paris maintains Affiliated Managers Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMG#NYSE">AMG</a>) with a Outperform and raises the price target from $200 to $240.

Barrington Research Maintains Outperform on Affiliated Managers Group, Raises Price Target to $240

Macquarie analyst Paul Golding maintains Visa (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/V#NYSE">V</a>) with a Outperform and raises the price target from $380 to $425.

Macquarie Maintains Outperform on Visa, Raises Price Target to $425

TD Securities analyst Cherilyn Radbourne maintains Canadian Pacific Kansas (TSX:<a class="ticker" href="https://www.benzinga.com/stock/CP#TSX">CP</a>) with a Hold and raises the price target from C$117 to C$118.

TSX:CP

TD Securities Maintains Hold on Canadian Pacific Kansas, Raises Price Target to C$118

TD Securities analyst Aaron Macneil maintains Precision Drilling (TSX:<a class="ticker" href="https://www.benzinga.com/stock/PD#TSX">PD</a>) with a Hold and raises the price target from C$71 to C$77.

TSX:PD

TD Securities Maintains Hold on Precision Drilling, Raises Price Target to C$77

UBS analyst Amit Mehrotra maintains Vertiv Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VRT#NYSE">VRT</a>) with a Buy and raises the price target from $135 to $173.

UBS Maintains Buy on Vertiv Holdings, Raises Price Target to $173

Pure Storage (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PSTG#NYSE">PSTG</a>) has outperformed the market over the past 5 years by 12.98% on an annualized basis producing an average annual return of 26.85%. Currently, Pure Storage has a market capitalization of $19.45 billion. 
Buying $1000 In PSTG: If an investor had bought $1000 of PSTG stock 5 years ago, it would be worth $3,290.22 today based on a price of $59.51 for PSTG at the time of writing.
<h3>Pure Storage's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1754003713_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

PSTG

Here's How Much $1000 Invested In Pure Storage 5 Years Ago Would Be Worth Today

Wells Fargo analyst Derek Archila maintains argenx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARGX#NASDAQ">ARGX</a>) with a Overweight and raises the price target from $741 to $756.

ARGX

Wells Fargo Maintains Overweight on argenx, Raises Price Target to $756

Citigroup analyst Joanne Wuensch maintains GE HealthCare Techs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GEHC#NASDAQ">GEHC</a>) with a Buy and raises the price target from $89 to $93.

GEHC

Citigroup Maintains Buy on GE HealthCare Techs, Raises Price Target to $93

Citigroup analyst Ronald Josey maintains Carvana (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVNA#NYSE">CVNA</a>) with a Buy and raises the price target from $415 to $490.

CVNA

Citigroup Maintains Buy on Carvana, Raises Price Target to $490

Citigroup analyst Ariel Rosa maintains United Parcel Service (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UPS#NYSE">UPS</a>) with a Buy and lowers the price target from $127 to $114.

Citigroup Maintains Buy on United Parcel Service, Lowers Price Target to $114

Citigroup analyst Yigal Nochomovitz maintains LENZ Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LENZ#NASDAQ">LENZ</a>) with a Buy and raises the price target from $45 to $49.

LENZ

Citigroup Maintains Buy on LENZ Therapeutics, Raises Price Target to $49

Citigroup analyst Asiya Merchant maintains Western Digital (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WDC#NASDAQ">WDC</a>) with a Buy and raises the price target from $78 to $88.

Citigroup Maintains Buy on Western Digital, Raises Price Target to $88

Citigroup analyst Ronald Josey maintains Meta Platforms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) with a Buy and raises the price target from $803 to $915.

Citigroup Maintains Buy on Meta Platforms, Raises Price Target to $915

BlackRock is going deeper into the hard hat area of the <a href="https://www.benzinga.com/etfs">ETF market.</a> The giant asset manager debuted its first-ever actively managed infrastructure ETF, the iShares Infrastructure Active ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BILT#NYSE">BILT</a>), on Thursday, a move that highlights the increasing popularity of infrastructure as a long-term growth vehicle.
For many decades, infrastructure investing was the investment equivalent of eating your vegetables, not thrilling but good for you. But with increasing global energy transitions, AI-hungry infrastructure that demands data and reconfigured supply chains, investors are now looking at infrastructure with fresh enthusiasm. BlackRock&#8217;s new ETF seeks to provide investors with diversified and agile exposure to this high-potential space.
Also Read: <a href="https://www.benzinga.com/etfs/broad-u-s-equity-etfs/25/07/46766110/4-unlikely-etfs-hit-52-week-highs-the-markets-just-catching-on-to-what-they-know">4 Unlikely ETFs Hit 52-Week Highs — The Market&#8217;s Just Catching On To What They Know</a>
<h2 class="wp-block-heading">How BILT&#8217;s Engine Is Built</h2>
The ETF includes 50 to 60 listed global infrastructure names, ranging from transport terminals to energy storage, utilities and building legends. Instead of passively following broad indexes, BILT employs an active strategy. The expense ratio of the ETF is 0.60%, and it tracks the FTSE Developed Core Infrastructure 50/50 Net TR Index.
The launch occurs as global infrastructure spending is expected to reach $68 trillion by 2040, driven by megatrends such as digitalization, energy independence, and supply chain reorganisation.
BILT complements BlackRock&#8217;s current $10 billion infrastructure ETF line-up consisting of:
<ul class="wp-block-list">
<li>iShares Global Infrastructure ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IGF#NASDAQ">IGF</a>)</li>
<li>iShares U.S. Infrastructure ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/IFRA#BATS">IFRA</a>)</li>
<li>iShares U.S. Digital Infrastructure and Real Estate ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IDGT#NYSE">IDGT</a>)</li>
</ul>
Simultaneously, BlackRock&#8217;s larger infrastructure business, Global Infrastructure Partners, oversees approximately $183 billion across 300-plus investments in more than 100 nations.
While infrastructure businesses tend to go unnoticed within global indexes, Morrison said that it&#8217;s precisely this under-allocation that makes BILT so strong. The ETF offers access to an asset class that has historically been less volatile than global equities, but without giving up growth opportunity.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/etfs/specialty-etfs/25/07/46763938/from-seoul-to-wall-street-how-trumps-south-korea-tariff-truce-could-reshape-etf-strategies">From Seoul To Wall Street: How Trump&#8217;s South Korea Tariff Truce Could Reshape ETF Strategies</a></li>
</ul>
Photo: Shutterstock

New ETFs

ETFs

BILT

iShares U.S. Digital Infrastructure and Real Estate ETF

IDGT

IFRA

iShares S&P Global Infrastructure Index Fund

BlackRock's New ETF BILT Bets On $68 Trillion Boom, But Most Investors Are Missing It

Citigroup analyst Ronald Josey maintains Fiverr Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FVRR#NYSE">FVRR</a>) with a Buy and lowers the price target from $40 to $33.

FVRR

Citigroup Maintains Buy on Fiverr Intl, Lowers Price Target to $33

Earnings

Press Releases

ProKidney Reports Third Quarter 2024 Financial Results along with Regulatory and Clinical Development Updates Following Successful FDA Type B Meeting

ProKidney to Participate in Two Upcoming Conferences: Evercore HealthCONx Conference and the Citi Global Healthcare Conference

ProKidney to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Kuehn Law Encourages Investors of ProKidney Corp. to Contact Law Firm

ProKidney Reports Full Year 2024 Financial Results and Business Highlights

ProKidney Reports First Quarter 2025 Financial Results and Business Highlights

ProKidney Corp. Completes Domestication from the Cayman Islands to Delaware

Health Care

ProKidney Reports Statistically and Clinically Significant Topline Results for the Phase 2 REGEN-007 Trial Evaluating Rilparencel in Patients with Chronic Kidney Disease and Diabetes

Comments

ProKidney

Noticias

Últimas noticias sobre ProKidney (NASDAQ:PROK) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL